- Home
- QNRX vs PRFX Comparison
QNRX vs PRFX Comparison
Compare QNRX & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNRX
- PRFX
- Stock Information
- Founded
- QNRX 2018
- PRFX 2007
- Country
- QNRX United States
- PRFX Israel
- Employees
- QNRX N/A
- PRFX N/A
- Industry
- QNRX Medical/Dental Instruments
- PRFX Biotechnology: Pharmaceutical Preparations
- Sector
- QNRX Health Care
- PRFX Health Care
- Exchange
- QNRX Nasdaq
- PRFX Nasdaq
- Market Cap
- QNRX 3.3M
- PRFX 3.6M
- IPO Year
- QNRX N/A
- PRFX 2020
- Fundamental
- Price
- QNRX $8.82
- PRFX $2.06
- Analyst Decision
- QNRX
- PRFX Hold
- Analyst Count
- QNRX 0
- PRFX 1
- Target Price
- QNRX N/A
- PRFX N/A
- AVG Volume (30 Days)
- QNRX 522.9K
- PRFX 55.9K
- Earning Date
- QNRX 05-13-2025
- PRFX 06-20-2025
- Dividend Yield
- QNRX N/A
- PRFX N/A
- EPS Growth
- QNRX N/A
- PRFX N/A
- EPS
- QNRX N/A
- PRFX N/A
- Revenue
- QNRX N/A
- PRFX N/A
- Revenue This Year
- QNRX N/A
- PRFX N/A
- Revenue Next Year
- QNRX N/A
- PRFX N/A
- P/E Ratio
- QNRX N/A
- PRFX N/A
- Revenue Growth
- QNRX N/A
- PRFX N/A
- 52 Week Low
- QNRX $5.01
- PRFX $1.68
- 52 Week High
- QNRX $54.95
- PRFX $18.17
- Technical
- Relative Strength Index (RSI)
- QNRX 57.93
- PRFX 51.59
- Support Level
- QNRX $8.67
- PRFX $1.93
- Resistance Level
- QNRX $9.30
- PRFX $2.11
- Average True Range (ATR)
- QNRX 0.62
- PRFX 0.10
- MACD
- QNRX 0.03
- PRFX 0.03
- Stochastic Oscillator
- QNRX 56.63
- PRFX 80.77
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.